Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Eloralintide in Severe Renal Impairment and ESRD
NCT07426380Phase 1Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2026
- Primary completion
- Oct 2026
- Countries
- 1
01
Overview
Phase 1, open-label trial of eloralintide in obesity and type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Zero to Infinity and Maximum Observed Drug Concentration. Started Feb 2026; status: active, not recruiting.
02
Drugs
eloralintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07426380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07426380.